Duke University Hospital Selects Compliance 360 Solution for Regulatory Management
Corporate Compliance Software Helps Hospital Keep Track of Ever-Changing Rules and Regulations
ATLANTA – July 27, 2005 – Compliance 360, a leading provider of corporate compliance management software for companies in regulated industries, announced today that Duke University Hospital has selected its platform as a hospital-wide regulatory information system and compliance automation solution.
"Before Compliance 360, significant resources were directed at keeping up with regulatory changes from the Centers for Medicare & Medicaid Services (CMS) and the Joint Commission on Accreditation of Healthcare Organizations (JCAHO)," said Gail Shulby, Director – Accreditation & Regulatory Affairs, Duke University Health System. "The challenge was predominantly around the changes in Medicare and Medicaid and the conditions for participation."
Duke University Hospital uses the Compliance 360 corporate compliance management system as an information management platform that automates the compliance review process. Gap analyses generated by the system allow Shulby and her staff to identify and track changes while taking action to stay in compliance. "A real business driver for us was that there was always the risk of being out of compliance with a regulation you did not know had changed," noted Shulby.
The system was deployed in early 2005 and currently has about 40 users who monitor the hospital's compliance to various regulatory standards, JCAHO and CMS conditions for participation.
"Like most large hospitals in the U.S., Duke University Hospital must constantly keep track of thousands of regulations, standards, codes, and accreditations that are continually changing," said Steve McGraw, CEO, Compliance 360. "Our corporate compliance management solution automates many of those processes and provides an enterprise-wide view of corporate compliance through a single interface."
Duke University Hospital employs over 5,700 people and has 995 hospital beds.
About Duke University Hospital
A tertiary and quaternary-care hospital, Duke University Hospital is consistently rated one of the top hospitals in the United States. It houses comprehensive diagnostic and therapeutic facilities including a regional emergency/trauma center; a major surgery suite with dedicated open-heart operating rooms; an endosurgery center; and an extensive diagnostic radiology area. The facility also functions as a research hospital where medical advances are achieved and applied, and as a teaching hospital for students of medicine, nursing, and the allied health sciences.
About Compliance 360
Compliance 360 provides corporate compliance management solutions that help companies in regulated industries address the most important facets of a comprehensive compliance program &emdash; reducing risks, reducing costs, improving efficiencies and enhancing global visibility of compliance activities. Compliance 360 has headquarters in Atlanta, GA and serves over 200 customers in healthcare, financial services, managed care, life sciences, pharmaceutical and other complex business environments. For more information, visit Compliance 360 at http://www.compliance360.com.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ifinatamab Deruxtecan Shows High Response Rates for Heavily Pretreated Small Cell Lung Cancer
September 9th 2024Potential first-in-class B7-H3 directed antibody drug conjugate ifinatamab deruxtecan shows potential to improve outcomes for patients living with difficult-to-treat form of lung cancer.
